The post As global growth falters, CHF stands out as a safe haven – Société Générale appeared on BitcoinEthereumNews.com. With Europe battling fiscal fragility, the US facing valuation risks, and China confronting disinflation, the Swiss franc may again prove resilient. History suggests that when rates and growth both roll over, the dollar eventually follows — though timing remains uncertain, Société Générale’s FX analyst Kit Juckes reports. USD range-bound, CHF gains appeal “How much history tells us about the future is debatable, but I find it useful to benchmark similar events. The 2023 regional bank crisis is a guide to the current woes of the sector, even if we also have to take into consideration the growth of the private credit market and the tightness of corporate bond spreads. Quarterly US GDP growth in 2023 of 2.9%, 2.5% 4.7% and 3.4% tells us not to overstate the “crisis, even though the US economy is slowing, rates are coming down, and this week’s September US CPI release is expected to show a 0.4% m/m headline increase, and annual inflation of 3.1% on both headline and core measures. Which won’t help real spending.” “Slowing growth and elevated equity valuations threaten either a 2011-style slowdown (2 non-consecutive quarters of falling GDP, 1.6% growth overall) or a mini-recession like 2001 (2 non-consecutive quarters of falling GDP after subsequent revisions, 1% growth overall. The Fed cut rates from 6 ½% to 1% from 2001 to 2003, and after peaking in 2001, the DXY fell by 40% over the coming 7 years. In 2011 the Fed merely kept rates anchored, and while the dollar fell in H1 2011 it ended the year unchanged before embarking on the 55% rally which saw it peak in 2022.” “If the US valuations are justifiable highly and US economic superiority remains unchallenged, rates will not fall far and we are in for a protracted period of range-bound exchange rates. But… The post As global growth falters, CHF stands out as a safe haven – Société Générale appeared on BitcoinEthereumNews.com. With Europe battling fiscal fragility, the US facing valuation risks, and China confronting disinflation, the Swiss franc may again prove resilient. History suggests that when rates and growth both roll over, the dollar eventually follows — though timing remains uncertain, Société Générale’s FX analyst Kit Juckes reports. USD range-bound, CHF gains appeal “How much history tells us about the future is debatable, but I find it useful to benchmark similar events. The 2023 regional bank crisis is a guide to the current woes of the sector, even if we also have to take into consideration the growth of the private credit market and the tightness of corporate bond spreads. Quarterly US GDP growth in 2023 of 2.9%, 2.5% 4.7% and 3.4% tells us not to overstate the “crisis, even though the US economy is slowing, rates are coming down, and this week’s September US CPI release is expected to show a 0.4% m/m headline increase, and annual inflation of 3.1% on both headline and core measures. Which won’t help real spending.” “Slowing growth and elevated equity valuations threaten either a 2011-style slowdown (2 non-consecutive quarters of falling GDP, 1.6% growth overall) or a mini-recession like 2001 (2 non-consecutive quarters of falling GDP after subsequent revisions, 1% growth overall. The Fed cut rates from 6 ½% to 1% from 2001 to 2003, and after peaking in 2001, the DXY fell by 40% over the coming 7 years. In 2011 the Fed merely kept rates anchored, and while the dollar fell in H1 2011 it ended the year unchanged before embarking on the 55% rally which saw it peak in 2022.” “If the US valuations are justifiable highly and US economic superiority remains unchallenged, rates will not fall far and we are in for a protracted period of range-bound exchange rates. But…

As global growth falters, CHF stands out as a safe haven – Société Générale

2025/10/20 19:39

With Europe battling fiscal fragility, the US facing valuation risks, and China confronting disinflation, the Swiss franc may again prove resilient. History suggests that when rates and growth both roll over, the dollar eventually follows — though timing remains uncertain, Société Générale’s FX analyst Kit Juckes reports.

USD range-bound, CHF gains appeal

“How much history tells us about the future is debatable, but I find it useful to benchmark similar events. The 2023 regional bank crisis is a guide to the current woes of the sector, even if we also have to take into consideration the growth of the private credit market and the tightness of corporate bond spreads. Quarterly US GDP growth in 2023 of 2.9%, 2.5% 4.7% and 3.4% tells us not to overstate the “crisis, even though the US economy is slowing, rates are coming down, and this week’s September US CPI release is expected to show a 0.4% m/m headline increase, and annual inflation of 3.1% on both headline and core measures. Which won’t help real spending.”

“Slowing growth and elevated equity valuations threaten either a 2011-style slowdown (2 non-consecutive quarters of falling GDP, 1.6% growth overall) or a mini-recession like 2001 (2 non-consecutive quarters of falling GDP after subsequent revisions, 1% growth overall. The Fed cut rates from 6 ½% to 1% from 2001 to 2003, and after peaking in 2001, the DXY fell by 40% over the coming 7 years. In 2011 the Fed merely kept rates anchored, and while the dollar fell in H1 2011 it ended the year unchanged before embarking on the 55% rally which saw it peak in 2022.”

“If the US valuations are justifiable highly and US economic superiority remains unchallenged, rates will not fall far and we are in for a protracted period of range-bound exchange rates. But if concerns about inflation, growth, asset valuations and market froth tip the scales and send the economy towards a recession, then rates and the dollar can both fall further than we expect. Amidst this uncertainty, we remain in wait-and-see mode. EUR/USD is trapped in a range, but there is merit in the NOK and SEK and the safe -haven qualities of the CHF, relative to the EUR and GBP. JPY can rally if Sanae Takaichi makes it clear that is appropriate; but despite excellent fundamentals, AUD may go on struggling as long as China is locked in dispute with the US and facing chronically weak domestic demand.”

Source: https://www.fxstreet.com/news/as-global-growth-falters-chf-stands-out-as-a-safe-haven-societe-generale-202510201012

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share